Noul Showcases AI-Driven Blood and Cancer Diagnostic Platform
Posted on 15 Nov 2023
Noul Co., Ltd. (Gyeonggi-do, Korea) is showcasing its AI-driven blood and cancer diagnostic platform, miLab, alongside its new product for automatically staining and analyzing cervical cells, at MEDICA 2023.
Based on its AI-based electro-dynamic blood diagnostic platform miLab, Noul offers various solutions. miLab MAL performs diagnostic processes from staining, and digital imaging to AI analysis with ~5µL of blood from fingertips and diagnoses malaria infection within 15 minutes by analyzing up to 300,000 red blood cells. miLab BCM performs diagnostic processes from staining, and digital imaging to AI analysis with ~5µL of blood obtained through fingertips or from veins. It provides high-definition digital images of white blood cells, red blood cells, and platelets, as well as pre-classification. miLab CER performs diagnostic processes from staining, and digital imaging to AI analysis on cervical cells and analyzes each cell’s characteristics to provide analysis results grouped into stages.
Noul’s new product unveiled at MEDICA 2023, ‘miLab Cartridge CER’ is designed for automatically staining and analyzing cervical cells. It stains cervico-vaginal samples smeared manually or by LBC using the Papanicolaou staining combined with NGSI, a solid-based staining technology developed by Noul. When used with miLab, Noul’s AI-based diagnostic platform, it provides staining, imaging, and cell analysis results that assist user’s decision-making. Through the launch of its new product, the company aims to contribute to the early diagnosis of cervical cancer, the fourth largest cancer in the world for women.
Related Links:
Noul Co., Ltd.
 Positive Control for Rapid Test.jpg)
